Insider trade

Director received an award of 147 ABBV derivative securities

Traded Dec 31, 2025 · Filed Jan 5, 2026

AbbVieABBV

147
Derivative units · @ $228.49

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 31, 2025
Reporting period: Not applicable
Filed with the SEC: Jan 5, 2026

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references dividend reinvestment

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001171780-26-000002
Filed / recorded

Jan 5, 2026, 10:00 PM UTC

Added to OQRO

Oct 2, 2026, 3:52 AM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

AbbVie Inc.

Issuer CIK

1551152

Ticker

ABBV

Reporting person

Edward J Rapp

Relationship

Director

Security

Stock Equivalent Units

Table

Derivative (Table II)

Transaction date

Dec 31, 2025

Transaction code

A

Shares / units

147

Price per share

$228.49

Acquired / disposed

Acquired (A)

Shares owned after

28,498

Ownership form

Direct

Amendment

No

Footnotes from the filing

Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.